COM:REVMED
Revolution Medicines
- Stock
40.64
+0.64%
3.42
This will be loaded shortly.
Loading
This is also still loading.
This will be loaded shortly.
Loading
This is also still loading.
This will be loaded shortly.
Loading
This is also still loading.
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inh...Show More